flebogamma 5 % dif
medici medical ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 0.5 g / 10 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott aldrich syndromemyeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.children with congenital aids and recurrent infections.immunomodulation :idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.guillain barré syndrome.kawasaki disease.allogeneic bone marrow transplantation
mestinon dragees 60 mg
megapharm ltd - pyridostigmine bromide - dragee - pyridostigmine bromide 60.0 mg - pyridostigmine - pyridostigmine - treatment of myasthenia gravis.
fortekor plus
elanco gmbh - benazepril hydrochloride, pimobendan - ace inhibitors, combinations - dogs - for the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.
lojuxta
amryt pharmaceuticals dac - lomitapide - hypercholesterolemia - lipid modifying agents - lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (ldl) apheresis in adult patients with homozygous familial hypercholesterolaemia (hofh). genetic confirmation of hofh should be obtained whenever possible. other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,
mabcampath
genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.
ozcrop clethodim 360 ec herbicide
oz crop pty ltd - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 360.0 g/l; liquid hydrocarbon solvent other 570.0 g/l - herbicide
mesna-claris mesna 200 mg/2 ml solution for injection ampoule
baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; nitrogen; sodium hydroxide - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).
mesna-claris mesna 400 mg/4 ml solution for injection ampoule
baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; water for injections; disodium edetate - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).
mesna-claris mesna 1000 mg/10 ml solution for injection ampoule
baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections; nitrogen; sodium hydroxide; disodium edetate; benzyl alcohol - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).
platinum xtra 360 herbicide
adama australia pty limited - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 360.0 g/l; liquid hydrocarbon solvent other 534.0 g/l - herbicide